Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Lazzarin

Showing results (281-290 of 288) with videos related to

Pageof 29
Sort By:
You have reached the last page of results.This site can display upto 288 results.
The New Microbiologica|November 17, 2015
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim ProjectMassimo Andreoni, Simone Marcotullio, Vincenzo Puro, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.
The New England Journal of Medicine|July 25, 2008
Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel, David A Cooper, Princy N Kumar, et al.
The New England Journal of Medicine|July 25, 2008
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper, Roy T Steigbigel, Jose M Gatell, et al.
Panminerva Medica|October 19, 2020
Biobanking for COVID-19 researchPatrizia Rovere-Querini, Cristina Tresoldi, Caterina Conte, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeksBenoit Trottier, Sharon Walmsley, Jacques Reynes, et al.
Plos One|November 19, 2010
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAARTBarbara Ensoli, Stefania Bellino, Antonella Tripiciano, et al.
The New Microbiologica|October 20, 2010
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study GroupValentina Svicher, Roberta D'Arrigo, Claudia Alteri, et al.
Pageof 29

Showing results (281-290 of 288) with videos related to

Sort By:
Pageof 29
You have reached the last page of results.This site can display upto 288 results.
The New Microbiologica|November 17, 2015
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim ProjectMassimo Andreoni, Simone Marcotullio, Vincenzo Puro, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.
The New England Journal of Medicine|July 25, 2008
Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel, David A Cooper, Princy N Kumar, et al.
The New England Journal of Medicine|July 25, 2008
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper, Roy T Steigbigel, Jose M Gatell, et al.
Panminerva Medica|October 19, 2020
Biobanking for COVID-19 researchPatrizia Rovere-Querini, Cristina Tresoldi, Caterina Conte, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeksBenoit Trottier, Sharon Walmsley, Jacques Reynes, et al.
Plos One|November 19, 2010
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAARTBarbara Ensoli, Stefania Bellino, Antonella Tripiciano, et al.
The New Microbiologica|October 20, 2010
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study GroupValentina Svicher, Roberta D'Arrigo, Claudia Alteri, et al.
Pageof 29